ID28210A - Turunan-turunan epotilon dan sintesa serta penggunaannya - Google Patents

Turunan-turunan epotilon dan sintesa serta penggunaannya

Info

Publication number
ID28210A
ID28210A IDW20002739A ID20002739A ID28210A ID 28210 A ID28210 A ID 28210A ID W20002739 A IDW20002739 A ID W20002739A ID 20002739 A ID20002739 A ID 20002739A ID 28210 A ID28210 A ID 28210A
Authority
ID
Indonesia
Prior art keywords
absent
single bond
alkyl
double bond
bond
Prior art date
Application number
IDW20002739A
Other languages
English (en)
Inventor
Maurice Raymond Verscho Finlay
Kyriacos Costa Nicolaou
Nigel Paul King
Yun He
Frank Roschangar
Dionisios Vourloumis
Hans Vallberg
Antony Bigot
Original Assignee
Novartis Ag Cs
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag Cs, Scripps Research Inst filed Critical Novartis Ag Cs
Publication of ID28210A publication Critical patent/ID28210A/id

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDW20002739A 1998-06-22 1999-06-21 Turunan-turunan epotilon dan sintesa serta penggunaannya ID28210A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/102,602 US6380394B1 (en) 1996-12-13 1998-06-22 Epothilone analogs

Publications (1)

Publication Number Publication Date
ID28210A true ID28210A (id) 2001-05-10

Family

ID=22290705

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002739A ID28210A (id) 1998-06-22 1999-06-21 Turunan-turunan epotilon dan sintesa serta penggunaannya

Country Status (28)

Country Link
US (3) US6380394B1 (id)
EP (2) EP1741715A1 (id)
JP (1) JP4681732B2 (id)
KR (3) KR100864742B1 (id)
CN (1) CN1192031C (id)
AT (1) ATE343573T1 (id)
AU (1) AU757854B2 (id)
BR (1) BR9911420A (id)
CA (1) CA2334342C (id)
CY (1) CY1105863T1 (id)
CZ (1) CZ301783B6 (id)
DE (1) DE69933767T2 (id)
DK (1) DK1089998T3 (id)
ES (1) ES2273502T3 (id)
HK (1) HK1038358A1 (id)
HU (1) HUP0102711A3 (id)
ID (1) ID28210A (id)
IL (3) IL139784A0 (id)
MX (1) MXPA00012443A (id)
NO (1) NO328417B1 (id)
NZ (1) NZ508622A (id)
PL (1) PL197648B1 (id)
PT (1) PT1089998E (id)
RU (1) RU2227142C2 (id)
SK (2) SK285647B6 (id)
TR (1) TR200003844T2 (id)
WO (1) WO1999067252A2 (id)
ZA (1) ZA200007059B (id)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
DE19820599A1 (de) * 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
JP4662635B2 (ja) 1998-11-20 2011-03-30 コーサン バイオサイエンシーズ, インコーポレイテッド エポチロンおよびエポチロン誘導体を生成するための組換え方法および材料
CZ301498B6 (cs) * 1999-02-22 2010-03-24 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epothilony
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP3222619A1 (en) 1999-04-15 2017-09-27 Bristol-Myers Squibb Holdings Ireland Cyclic protein tyrosine kinase inhibitors
WO2001038317A2 (en) * 1999-11-24 2001-05-31 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Fungicidal melithiazole derivatives
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
CA2422500A1 (en) * 2000-09-22 2003-03-18 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Triazolo-epothilones
IL155306A0 (en) * 2000-10-13 2003-11-23 Univ Mississippi Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
CN1489466A (zh) 2001-01-25 2004-04-14 ����˹�ж�-����˹˹������˾ 包含埃博霉素类似物的非肠道制剂
CZ20032021A3 (cs) 2001-01-25 2004-05-12 Bristol@Myersásquibbácompany Způsoby podávání analogů epothilonu při léčbě rakoviny
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
IL156988A0 (en) 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
KR20040028720A (ko) 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
IL157312A0 (en) * 2001-02-27 2004-02-19 Biotechnolog Forschung Gmbh Processes for the preparation of epothilone derivatives and compounds produced thereby
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
WO2002098868A1 (en) * 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Epothilone derivatives
CA2456280A1 (en) * 2001-08-23 2003-03-06 Novartis Ag Cyclopropyl and cyclobutyl epothilone analogs
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
IL161462A0 (en) * 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
WO2003048774A1 (en) * 2001-12-07 2003-06-12 Novartis Ag Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
EP1469847A1 (en) 2002-01-14 2004-10-27 Novartis AG Combinations comprising epothilones and anti-metabolites
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
SI1483251T1 (sl) * 2002-03-12 2010-03-31 Bristol Myers Squibb Co C cian epotilonski derivati
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
JP4276171B2 (ja) * 2002-08-02 2009-06-10 ノバルティス アクチエンゲゼルシャフト エポシロン誘導体
WO2004018478A2 (en) * 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
KR101406635B1 (ko) 2002-09-23 2014-06-11 브리스톨-마이어스 스큅 컴퍼니 에포틸론 b의 제조, 분리 및 정제 방법, 및 에포틸론 b의 x-선 결정 구조
WO2004035050A1 (en) * 2002-10-15 2004-04-29 Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College Use of epothilone derivatives for the treatment of hyperparathyroidism
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
US7893268B2 (en) * 2005-07-27 2011-02-22 University Of Toledo Epithiolone analogues
WO2007062288A2 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7653731B2 (en) * 2006-02-24 2010-01-26 Microsoft Corporation Management of connections to external data
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
BRPI0718360A2 (pt) 2006-12-04 2013-11-12 Univ Illinois "composições e métodos para o tratamento do câncer com cupredoxinas e dna rico em cpg"
EP2114429A4 (en) 2007-02-08 2010-05-19 Univ Illinois COMPOSITIONS AND METHODS FOR PREVENTING CANCER WITH CUPREDOXINS
WO2008118327A1 (en) * 2007-03-23 2008-10-02 University Of Toledo Conformationally restrained epothilone analogues as anti-leukemic agents
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2321325A1 (en) * 2008-07-03 2011-05-18 Pharma Mar S.A. Antitumoral macrolides
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
MX356514B (es) 2011-01-20 2018-05-30 Univ Texas Marcadores de formación de imagen por resonancia magnética, sistemas de suministro y extracción, y métodos de fabricación y uso de los mismos.
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
US9725477B2 (en) 2012-11-17 2017-08-08 Beijing Fswelcome Technology Development Co., Ltd Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
CA2898996A1 (en) * 2013-01-23 2014-07-31 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. ポリペプチドの酵素的結合
WO2017066606A1 (en) * 2015-10-16 2017-04-20 William Marsh Rice University Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
AU753546B2 (en) 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
CN1544436A (zh) 1997-02-25 2004-11-10 ���\���о����޹�˾��GBF�� 3,7-保护的环氧噻嗪酮-n-氧化物及其制备方法
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
IL134419A0 (en) 1997-08-09 2001-04-30 Schering Ag Epothilone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

Also Published As

Publication number Publication date
AU757854B2 (en) 2003-03-06
RU2227142C2 (ru) 2004-04-20
CN1192031C (zh) 2005-03-09
EP1089998B1 (en) 2006-10-25
IL182744A0 (en) 2007-07-24
CZ301783B6 (cs) 2010-06-23
EP1741715A1 (en) 2007-01-10
DK1089998T3 (da) 2007-01-15
BR9911420A (pt) 2001-03-20
IL139784A (en) 2010-05-17
MXPA00012443A (es) 2004-12-03
JP2002518504A (ja) 2002-06-25
PL197648B1 (pl) 2008-04-30
NO328417B1 (no) 2010-02-15
SK19712000A3 (sk) 2001-09-11
PT1089998E (pt) 2007-01-31
DE69933767D1 (de) 2006-12-07
KR20080045298A (ko) 2008-05-22
IL182744A (en) 2010-05-17
US6531497B1 (en) 2003-03-11
AU4774899A (en) 2000-01-10
JP4681732B2 (ja) 2011-05-11
CA2334342A1 (en) 1999-12-29
US7579366B2 (en) 2009-08-25
CA2334342C (en) 2012-07-17
NZ508622A (en) 2003-07-25
PL345327A1 (en) 2001-12-17
HK1038358A1 (en) 2002-03-15
US20030203938A1 (en) 2003-10-30
US6380394B1 (en) 2002-04-30
ATE343573T1 (de) 2006-11-15
SK287864B6 (sk) 2012-02-03
HUP0102711A3 (en) 2002-09-30
SK285647B6 (sk) 2007-05-03
IL139784A0 (en) 2002-02-10
KR20090066332A (ko) 2009-06-23
CY1105863T1 (el) 2011-02-02
EP1089998A2 (en) 2001-04-11
WO1999067252A3 (en) 2000-03-16
TR200003844T2 (tr) 2001-04-20
ZA200007059B (en) 2002-01-30
KR20010083060A (ko) 2001-08-31
NO20006378L (no) 2001-02-21
WO1999067252A2 (en) 1999-12-29
CZ20004769A3 (cs) 2001-07-11
DE69933767T2 (de) 2007-09-13
CN1306531A (zh) 2001-08-01
HUP0102711A2 (hu) 2001-12-28
NO20006378D0 (no) 2000-12-14
ES2273502T3 (es) 2007-05-01
KR100864742B1 (ko) 2008-10-22

Similar Documents

Publication Publication Date Title
ID28210A (id) Turunan-turunan epotilon dan sintesa serta penggunaannya
ES2153927T3 (es) Intermedios de dioxolano.
DE69331414D1 (de) Depsipeptide, herstellung und anwendung
ATE250573T1 (de) Azetidin- und pyrrolidinderivate
AU689304B2 (en) Quinazoline derivative
DK0565721T3 (da) 1,4-Benzothiazepinderivat
DE60215656D1 (de) Photostabile organische sonnenschutzmittel mit antioxidativen eigenschaften und zusammensetzungen damit
GB9202378D0 (en) Inventions relating to fungicidal compositions
DK0919126T3 (da) Hidtil ukendte landbrugsmæssige/havebrugsmæssige baktericide sammensætninger
ATE417898T1 (de) Durch sprühtrocknung herstellbare staubfreie pigmentzusammensetzungen
NO175253C (no) Forbindelse, anvendelse og preparat
DE69431461T2 (de) Lausabweisende Zusammensetzungen
AU7156694A (en) Thienyl- and furylpyrrole insecticidal and acaricidal agents
ATE105565T1 (de) Pradimicinderivate.
ES2125863T3 (es) Control de microorganismos en plantas con 1-hidroximetilpirazoles.